C4 Therapeutics, Inc. (CCCC) Tops Q2 EPS by 3c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Trifecta Gold closes $1.66M private placement for Yukon exploration
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform